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atrick Gladding, MBCHB,*‡ Harvey White, MBCHB, DSC,* Jamie Voss, MBCHB,*
ohn Ormiston, MBCHB,* Jim Stewart, MBCHB,* Peter Ruygrok, MD, MBCHB,*
adi Bvaldivia,† Ruth Baak, PHD,† Catherine White, MBCHB,* Mark Webster, MBCHB*
uckland, New Zealand; and Carlsbad, California
bjectives Our aim was to assess whether a higher clopidogrel maintenance dose has a greater
ntiplatelet effect in CYP2C19*2 allele carriers compared with noncarriers.
ackground Clopidogrel is a prodrug that is biotransformed by the cytochrome P450 enzymes
YP2C19, 2C9, and 3A4, 2B6, 1A2. The CYPC219*2 loss of function variant has been associated with
reduced antiplatelet response to clopidogrel and a 3-fold risk of stent thrombosis.
ethods Forty patients on standard maintenance dosage clopidogrel (75 mg), for 9.4  9.2 weeks,
ere enrolled into a dose escalation study. Platelet function was assessed at baseline and after 1
eek of 150 mg once daily using the VerifyNow platelet function analyzer (Accumetrics Ltd., San
iego, California). Genomic DNA was hybridized to a BioFilmChip microarray on the INFINITI ana-
yzer (AutoGenomics Inc., Carlsbad, California) and analyzed for the CYP19*2, *4, *17, and CYP2C9*2,
3 polymorphisms.
esults Platelet inhibition increased over 1 week, mean 8.6  13.5% (p  0.0003). Carriers of the
YP2C19*2 allele had signiﬁcantly reduced platelet inhibition at baseline (median 18%, range 0% to
2%) compared with wildtype (wt) (median 59%, range 11% to 95%, p  0.01) and at 1 week (p 
.03). CYP2C19*2 allele carriers had an increase in platelet inhibition of (mean 9  11%, p  0.03)
nd reduction in platelet reactivity (mean 26  38 platelet response unit, p  0.04) with a higher
ose. Together CYP2C19*2 and CYP2C9*3 loss of function carriers had a greater change in platelet
nhibition with 150 mg daily than wt/wt (10.9% vs. 0.7%, p  0.04).
onclusions Increasing the dose of clopidogrel in patients with nonresponder polymorphisms can
ncrease antiplatelet response. Personalizing clopidogrel dosing using pharmacogenomics may be an
ffective method of optimizing treatment. (J Am Coll Cardiol Intv 2009;2:1095–101) © 2009 by the
merican College of Cardiology Foundation
rom the *Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand; †AutoGenomics, Carlsbad,
alifornia; and ‡Theranostics Lab (NZ) Ltd., Auckland, New Zealand. Drs. Gladding and Webster have filed a PCT 61/023596
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1096lopidogrel is an antiplatelet agent that blocks the
denosine diphosphate (P2Y12) receptor and prevents
therothrombotic events (1). The response to clopidogrel
hows wide population variability (2), and up to 5% to
0% of patients may not respond to the drug (3,4).
lopidogrel is a pro-drug that requires conversion to its
ctive thiol derivative, and this is catalyzed by the
ytochrome P450 enzyme system. While (CYP) 3A4,
A5, 2C19, 2C9, and 1A2 may be relevant in this
onversion (5–7), only loss of function polymorphisms
ithin the 2C19 gene have been associated with a
educed clinical response to clopidogrel (8 –11).
See page 1102
The genetic polymorphisms within the CYP2C19 gene
re denoted by the star nomenclature. The more common
YP2C19*2, *3, and *4 alleles display a loss of function,
hile CYP2C19*17 is associated with ultrarapid enzyme
ctivity (9). The mechanism behind nonresponse is hypoth-
sized to be reduced exposure to the active metabolite of
lopidogrel. While heterozygotes for the loss of function
llele may still be able to convert some of clopidogrel to its
active form, rarer homozygotes
may be incapable of any conver-
sion (5). Furthermore, the fre-
quency of the *2 allele and rarer
loss of function variants are
more common in some ethnic
groups.
Recent attention has been
rawn to the clinical importance of these genetic variants
9). Most of these studies have shown a consistent increase
n the risk of stent thrombosis in genetic nonresponders
aking clopidogrel (9–12). In the TRITON–TIMI 28
Trial to Assess Improvement in Therapeutic Outcomes by
ptimizing Platelet Inhibition with Prasugrel–Thrombolysis
n Myocardial Infarction 28) study, there was a higher
ncidence of the composite of ischemic events and cardio-
ascular death in those carrying the CYP2C19*2 allele who
eceived clopidogrel. In contrast, the CYP2C19*2 allele
arriers receiving prasugrel did not face the same risk of
schemic events or death and, interestingly, did not display
trade-off with increased bleeding on prasugrel (13).
lternatively, loss of function allele carriers may respond to
igher doses of clopidogrel (14).
Individualizing treatment, using genotyping, may allow
ost effective targeting of treatment or introduction of new
herapies. This might improve outcomes without increasing
dverse events. This study assesses genotyping in a cohort in
hich a clopidogrel dose was escalated over a week. We
tilized a genotyping platform capable of rapid results
bbreviations and
cronyms
I  confidence interval
PI  proton pump inhibitor
RU  platelet response
niturnaround. aethods
tudy population. The study protocol was approved by the
orthern Regional Ethics Committee of New Zealand and
egistered with the Australian New Zealand Clinical Trials
egistry, ACTRN12606000129583. Patients were individ-
als who had undergone percutaneous coronary intervention
2 weeks before enrollment. Exclusion criteria were: a
leeding or inherited platelet disorder, gastrointestinal
leeding or gastric ulcer/duodenal ulcer/gastritis within the
ast 6 months, sensitivity/allergy to aspirin/clopidogrel,
enal failure (creatinine clearance estimate glomerular filtra-
ion rate30 ml/min), anemia (hemoglobin115 g/l), and
hrombocytopenia (platelet count 150  109/l).
tudy design. The study was an open label dose escalation
tudy with molecular randomization.
ypothesis. The primary hypothesis was that an increased
lopidogrel dose would increase platelet response in
YP2C19*2 allele carriers. The secondary hypothesis was
hat carriers of the CYP2C19*2 allele would have a greater
hange in platelet inhibition, with an increased dose of
lopidogrel over 1 week, than wildtype individuals. A
ost-hoc analysis included the addition of CYP2C9*3 allele
arriers to CYP2C19*2 carriers, to assess the change in
esponse (delta) of a higher dose compared with wildtype.
n interaction with proton pump inhibitors (PPIs) was also
ssessed.
tudy protocol. Forty patients already taking 75 mg daily of
lopidogrel had a baseline platelet function test performed,
ollowed by a dose increase to 150 mg daily for 1 week.
lood sampling. Venous blood was sampled using a vacu-
ainer technique and collected into 2-ml 3.2% citrate tubes
Greiner Vacuette, Greiner, Kremsmuenster, Austria), us-
ng a 20-gauge needle and syringe. The collection tubes
ere inverted 4 times to mix the anticoagulant and left for
0 min at ambient temperature (24°C) before testing.
latelet function was tested at baseline and at 7 days. Whole
lood for DNA extraction was taken in EDTA tubes.
latelet function analysis. Platelet function was measured
sing the VerifyNow point-of-care rapid platelet function
nalyzer and its P2Y12 cartridge (Accumetrics Ltd., San
iego, California). This device uses fibrinogen-coated mi-
robeads, an agonist of adenosine diphosphate (20 mmol/l),
nd light transmittance through whole blood, to measure
latelet agglutination. The P2Y12 cartridge result correlates
avorably with light transmittance aggregometry (15), with
eported increased sensitivity to the P2Y12 receptor due to
he addition of prostaglandin E2 (22 nmol/l) to the reaction
hamber (2). Platelet inhibition is reported as the percent-
ge change in the platelet response unit (PRU) from a
aseline (BASE) unit, derived from a second channel run in
arallel with the adenosine diphosphate channel using the



































































J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 1 1 , 2 0 0 9 Gladding et al.
N O V E M B E R 2 0 0 9 : 1 0 9 5 – 1 0 1 Clopidogrel Dose Escalation Pharmacogenetics Study
1097RU indicates greater platelet inhibition, but this is not
ontrolled for the effect of thrombin.
enotyping. Genomic DNA was extracted from whole
lood using a MiniAmp extraction kit (Qiagen, Venlo, the
etherlands). Multiplex amplification of each sample was
erformed in an individual well of a 24-well plate using an
ppendorf Mastercycler (Hamburg, Germany). Template
nd Platinum Taq Polymerase (Life Technologies, Carls-
ad, California) were added to an analyte-specific amplifi-
ation mix (AutoGenomics Inc., Carlsbad, California).
fter amplification, the plate was placed in the INFINITI
nalyzer (AutoGenomics Inc.) where detection primer ex-
ension occurred, followed by hybridization of detection
rimers to individual oligonucleotides arrayed on the Bio-
ilmChip. After hybridization, the BioFilmChips were
ashed and scanned in the INFINITI optics module.
The Autogenomics 2C19 and 2C9-VKORC1 assays
ere used to detect the presence of CYP2C19*2, *3, *4, *5,
6, *7, *8, *10, and *17 and CYP2C9*2, *3, *4, *5, *6, and *1
olymorphisms, respectively. These tests were performed
fter the second platelet function test, and the results were
etrospectively assessed. CYP2C19*2 and CYP2C9*3 but
xcluding CYP2C19*17 carriers were classified at poor
etabolizers. Combined carriers of CYP2C19*17 and *2 and
ildtype/wildtype were considered intermediate metaboliz-
rs. CYP219*17 carriers without CYP2C19*2 or CYP2C9*3
lleles were classified as ultrametabolizers).
tatistics. The numbers of patients required to reach statis-
ical power were calculated using figures for platelet inhibi-
ion effected by higher doses of clopidogrel (14). We
Table 1. Patient Baseline Characteristics (n  40)
Men 31 (78%)
Caucasian* 35 (88%)
Age (yrs) 67 11
Weight (kg) 87 16
Creatinine (mg/dl) 1.01 0.16
Weeks on clopidogrel 9.4 9.2
Number given 600-mg loading dose 39 (98%)
Past medical history
Type II diabetes 8 (20%)
Hypertension 20 (50%)
Dyslipidemia 17 (43%)
Congestive heart failure 2 (5%)
Smoker 4 (10%)
Coronary bypass surgery 5 (13%)
Percutaneous coronary intervention 35 (88%)
Family history of coronary artery disease 7 (18%)
Interacting medication
Omeprazole 13 (33%)
Other CYP3A4, 2C19 drug 0
Values given as n (%) ormean SD. *Other ethnicity includedMaori (n 2), Fijian Indian (n 2),
Chinese (n 1).stimated a study of 40 patients would provide90% powero detect the influence of genotypes on platelet function at
significance level of 0.05. The primary output of interest
rom the VerifyNow (Accumetrics) instrument was platelet
nhibition, but where a result using this variable was not
tatistically significant the platelet response unit has been
eported. The Student t test was applied where the data was
arametric and are reported in mean SD when paired and
ean and 95% confidence interval (CI) when unpaired. The
ilcoxon rank sum test was used for the nonparametric
latelet percentage inhibition data and reported as median
nd range. The software used for analysis was MedCalc
ersion 7.3.0.1 (MedCalc Software, Mariakerke, Belgium).
esults
ne patient did not complete the study protocol due to
onattendance at 1 week. There were no bleeding episodes.
ne DNA sample was insufficient for analysis. Baseline
haracteristics of the patients are outlined in Table 1. The
llelic frequencies of the polymorphisms are outlined in
able 2. A number of individuals were compound heterozy-
otes, but they were insufficient in number to evaluate
ene-gene interactions. Platelet inhibition at baseline for
ach allelic group is shown in Figure 1.
Platelet inhibition on average increased over 1 week,
ean 8.6  13.5% (p  0.0003) (Fig. 2). Carriers of the
YP2C19*2 allele had significantly reduced platelet inhibi-
ion at baseline (median 18%, range 0% to 72%) compared
ith wildtype (wt/wt) (59%, 11% to 95%, p  0.01) and at
week (p  0.03).
A paired comparison of baseline results with results at 7
ays showed that platelet inhibition could be increased in
YP2C19*2 allele carriers with an increased dose of clopi-
ogrel. A mean increase in platelet inhibition of mean9
1% (p  0.03) and reduction in platelet reactivity (mean
26  38 PRU, p  0.04) was seen in CYP2C19*2 carriers
ith a higher dose (Fig. 3).
Together CYP2C19*2 and CYP2C9*3 loss of function
arriers had a greater change in platelet inhibition with 150
g daily than wt/wt (	mean10%, 95% CI:20 to0.1,
 0.05) (Fig. 4).














CYP2C19 *2 rs4244285 13 33%
*3 rs1057910 0 0%
*17 rs12248560 18 46%
CYP2C9 *2 rs1799853 6 15%
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1098Omeprazole (n  12) or lansoprazole (n  1) were being
aken by 33% (n  13) of individuals. Patients on these
PIs, which are metabolized by CYP2C19, had a lower
ercentage platelet inhibition (median 14%, average rank
6 to 22, p  0.18) and a higher platelet reactivity (mean
51 PRU, 95% CI: 7 to 110, p  0.08) suggesting a
rug-drug interaction, leading to a reduced response to
lopidogrel. After 1 week of therapy, those taking these
PIs still had lower platelet inhibition than those not on
PIs (mean 10% inhibition, 95% CI: 8 to 27, p  0.3).
owever, compared with baseline, those on a PPI had a
ignificant increase in platelet inhibition after 1 week of a
Figure 1. Baseline Platelet Inhibition
Platelet function demonstrated for each genotype group.
Figure 2. Platelet Function at Baseline (75 mg) and 7 Days (150 mg)
Platelet function at baseline in patients on 75 mg once daily clopidogrel
and after 1 week of 150 mg daily. Variable responses but overall a mean
increase in platelet inhibition is demonstrated.igher dose (mean9 10%, p 0.007), showing that the
nfluence of the PPI could be overcome. Those on PPIs had
trend toward a greater change in platelet inhibition than
hose not on PPIs (	 median 15% inhibition, 95% CI: 3
o 16 vs. 	median 7% inhibition, 95% CI:2 to 13, p 0.3)
Fig. 5). Only 1 CYP2C19*2 carrier was on omeprazole.
iscussion
his study addressed the question of whether increasing a
ose of clopidogrel from 75 mg once daily to 150 mg once
Figure 3. Platelet Function in CYP2C19*2 Carriers at Baseline
and 7 Days
Platelet function at baseline in CYP2C19*2 carriers and after 1 week of 150
mg daily clopidogrel. An improvement in platelet inhibition is seen in most
patients.
Figure 4. Change in Percentage Platelet Inhibition in CYP2C19*2 Carriers
Box plots represent median, range, and 25th and 75th quartiles. See text
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1099aily for 1 week increases clopidogrel’s antiplatelet response
n genetic nonresponders. The results show that platelet
nhibition can be increased in individuals carrying the
oss-of-function CYP2C19*2 allele by giving higher doses of
lopidogrel. This supports our previous study (14). How-
ver, despite a dose of 150 mg once daily, there is still a
trong influence of this variant on platelet function, and the
mall improvement in platelet inhibition may not translate
nto clinical significance. There was also a trend to a reduced
ntiplatelet response to clopidogrel in those taking omepra-
ole, a drug metabolized also by the CYP2C19 enzyme.
his drug-drug interaction may also be overcome by in-
reasing the dose of clopidogrel.
Several studies have linked an increased risk in stent
hrombosis and major adverse cardiac events to carriers of
he CYP2C19*2 polymorphism (8–12). One conflicting
esult, however, has been demonstrated in the FAST-MI
French Registry of Acute ST-Elevation and Non–ST-
levation Myocardial Infarction) study, which showed an
ncreased event rate in *2 homozygotes but a reduced event
ate in heterozygotes, compared with wildtype homozygotes
11). The reason for this paradoxical finding is not clear.
With the availability of the novel third-generation thien-
pyridine prasugrel, the potential for targeting treatment
ppears appealing; however, increasing the dose of clopi-
ogrel in some individuals may be sufficient to make them
esponders. A study looking at just phenotypic nonre-
ponders, using vasodilator-stimulated phosphoprotein
howed an increase in suppression of platelet function with
n increased clopidogrel dose, independent of the
YP2C19*2 allele (16). Another study, using doses up to
.4 g in a widely spaced iterative loading protocol has shown
Figure 5. Change in Percentage Platelet Inhibition Over 1 Week in
Patients on PPI
Increase in platelet inhibition after 1 week of 150 mg daily clopidogrel, in
patients taking proton pump inhibitors (PPIs).he existence of a core group of phenotypic nonresponders f17). Whether this profound nonresponsiveness is geneti-
ally determined is unknown. We have shown that a
ractical method of clopidogrel loading using 1,200 mg split
ver 2 h results in a mean increase of 20% platelet
nhibition (VerifyNow, Accumetrics), 7 h after loading,
ompared with 600 mg (p  0.03) (18).
The functional relevance of rarer CYP2C19 variants
eeds further investigation. The CYP2C19*3 allele, coding
or a truncated enzyme protein, is particularly prevalent in
ome populations, such as East Asians and those of East
sian descent such as Pacific Peoples and Maori (19,20).
his variant, however, has not been detected in any of the
tudies performed to date (8–12,21). Together the *3 and *2
ariants account for 99% of all poor metabolizers in East
sians and both would need to be considered if clinical
enotyping for clopidogrel was being considered in Asian
ountries (22). We have shown that the rare loss of function
YP2C19*4 allele has an effect on the platelet response to
lopidogrel (14). This variant is more common in those of
shkenazi descent and ignoring this variant in a genotyping
anel can lead to misclassification of phenotypic nonre-
ponders (23). Figure 1 shows that genotyping alone will
isclassify some individuals who have satisfactory platelet
nhibition and vice versa. The biotransformation of clopi-
ogrel requires a 2-step CYP-dependent process (24).
ene-gene interactions require further study as a combina-
ion of single nucleotide polymorphisms may allow better
isk stratification for cardiovascular events and further en-
ance treatment decisions. Pharmacogenetics is unlikely to
ncapsulate the whole picture, and response prediction is
ikely to be enhanced by the incorporation of phenotype
easures (Fig. 6) (12,25).
The importance of the CYP2C9*3 allele (2C9 being
elated to 2C19) with respect to the clopidogrel biotrans-
Figure 6. Clopidogrel Response Incorporating Static and Variable Factors
CES  carboxylesterase; CVA  stroke; hPXR  human pregnane X recep-
tor; IL  interleukin; TNF  tumor necrosis factor; T2DM  type II diabetes;
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1100ertain. Pharmacokinetic/pharmacodynamic data suggest
hat it is an important variant (26); however, a larger
harmacokinetic study with clinical outcome data has
hown no effect (9). This may be due to sequence homology
r 2C9 primer issues leading to genotyping errors (27).
The interaction between proton pump inhibitors and
lopidogrel has received recent attention (28). Both ome-
razole (28–31) and lansoprazole (24) have been shown to
educe the responsiveness to clopidogrel, whereas pantopra-
ole (29,31,32) and esomeprazole (29,32) (the S-enantiomer of
meprazole) have not. In this study, the patients taking
meprazole or lansoprazole had a trend toward a lower than
verage platelet response suggesting a drug-drug interac-
ion. In this study, a higher dose of clopidogrel was able to
artly overcome the clopidogrel-PPI interaction.
Rapid genotyping will be necessary for pharmacogenom-
cs to be useful in the clinical setting. The INFINITI
nalyzer provides a rapid turnaround time in 8 h. Other
echnologies exist offering faster genotyping, but some are
ot capable of multiplexing beyond a certain number of
NPs (33). Examples of rapid genotyping include high
esolution melt curve analysis, used in warfarin pharmaco-
enetic studies (34) and direct nucleic acid detection using
old nanoparticles. This has the advantage of a polymerase
hain reaction-free environment; 1 h result turnaround and
ay only require a single drop of blood to perform an
nalysis (35).
On the flip side of nonresponse to clopidogrel is the
otential for an excessive antiplatelet response and bleeding.
ual antiplatelet therapy is associated with a reduction in
ardiovascular event rates but also a rise in bleeding events
ompared with aspirin alone (36). One of the limiting
actors to the acceptance of prasugrel has been the concern
egarding bleeding events. Patient characteristics such as an
ge 75 years of age, weight 60 kg, or presence of
revious ischemic stroke are risk factors identified with
leeding events on prasugrel (37). Prescribing prasugrel,
nstead of clopidogrel, to patients with diabetes and patients
ndergoing elective or acute primary PCI, may improve the
ost-benefit ratio (13,38).
tudy limitations. There are a number of limitations of this
tudy, mainly related to lack of statistical power. Genotyp-
ng was also performed retrospectively. Despite showing the
bility to enhance platelet response in CYP2C19*2 allele
arriers with higher doses of clopidogrel, this may not be
linically significant. We had no measure of treatment
dherence. Tachyphylaxis may have influenced the variabil-
ty in baseline response.
onclusions
his study has shown that higher doses of clopidogrel, for
ome individuals, may improve the antiplatelet response.
urther study is required to assess whether there is a
1herapeutic window for thienopyridines, balancing effective-
ess and bleeding. Targeting treatment based on nonre-
ponse using either phenotyping, genotyping, or both may
e more cost-effective than a “one-size-fits-all” strategy.
ntegrating important clinical, genetic, and phenotypic data
s complex, and decision support software may be required
o optimize prescribing (21). Prospective studies, applying
harmacogenetics before treatment is given, are required to
rove the cost-effectiveness and clinical usefulness of this
pproach.
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